Skip to main content

Edwards Lifesciences Corporation (EW)

NYSE: EW · IEX Real-Time Price · USD
119.46
3.94 (3.41%)
At close: Dec 8, 2021 4:00 PM
119.75
0.29 (0.24%)
After-hours:Dec 8, 2021 7:51 PM EST
Market Cap74.58B
Revenue (ttm)5.09B
Net Income (ttm)1.48B
Shares Out624.33M
EPS (ttm)1.35
PE Ratio88.55
Forward PE42.74
Dividendn/a
Ex-Dividend Daten/a
Volume3,263,210
Open116.04
Previous Close115.52
Day's Range115.70 - 119.62
52-Week Range78.44 - 123.27
Beta1.07
AnalystsBuy
Price Target119.36 (-0.1%)
Earnings DateOct 27, 2021

About EW

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve re...

IndustryHealth Care Equipment & Supplies
IPO DateMar 27, 2000
CEOMichael Mussallem
Employees14,900
Stock ExchangeNYSE
Ticker SymbolEW
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for EW stock is "Buy." The 12-month stock price forecast is 119.36, which is a decrease of -0.08% from the latest price.

Price Target
$119.36
(-0.08% downside)
Analyst Consensus: Buy

News

Edwards Lifesciences CEO on outlook for 2022: 'We are just getting started'

Edwards Lifesciences CEO Michael Mussallem appeared on Wednesday's episode of "Mad Money," after the medical technology firm held its annual investor conference.

5 hours ago - CNBC Television

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

IRVINE, Calif., Dec. 8, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and shar...

16 hours ago - PRNewsWire

Here's Why You Should Retain Edwards Lifesciences (EW) Stock

Investors are optimistic about Edwards Lifesciences (EW) on strong third-quarter results and bullish 2021 guidance.

3 weeks ago - Zacks Investment Research

Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program

IRVINE, Calif., Nov. 6, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced that results from a clinical trial of the company's EVOQUE transcatheter tricuspid valve replacement sy...

1 month ago - PRNewsWire

TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis

IRVINE, Calif., Nov. 5, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonst...

1 month ago - PRNewsWire

More Treats Than Tricks In Halloween Market Rally; Edwards Lifesciences, Google, Xpeng Near Buys

More Treats Than Tricks In Halloween Market Rally; Edwards Lifesciences, Google, Xpeng Near Buys Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lis...

Other symbols:XPEVGOOGGOOGL
1 month ago - Investors Business Daily

Edwards Lifesciences (EW) Beats on Q3 Earnings, Gross Margin Up

Strong sales growth across all four products group along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) third-quarter revenues.

1 month ago - Zacks Investment Research

Edwards Lifesciences (EW) Tops Q3 Earnings Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 1.89% and -0.92%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Edwards Lifesciences Reports Third Quarter Results

IRVINE, Calif., Oct. 27, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2021.

1 month ago - PRNewsWire

Medical Products Stock Q3 Earnings on Oct 27: TMO, EW & More

With the pandemic raging on, testing, vaccine and therapeutic makers witness huge market adoption of their COVID-related support products in Q3.

Other symbols:ALGNBSXTMO
1 month ago - Zacks Investment Research

Edwards Lifesciences To Host Earnings Conference Call On October 27, 2021

IRVINE, Calif., Oct. 20, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2021 after the market closes on Wednesday, Octob...

1 month ago - PRNewsWire

OCPNY or EW: Which Is the Better Value Stock Right Now?

OCPNY vs. EW: Which Stock Is the Better Value Option?

1 month ago - Zacks Investment Research

Edwards Lifesciences (EW) to Post Q3 Earnings: What's in Store?

Improvement in Critical Care and Surgical Structural Heart businesses is expected to have contributed to Edwards Lifesciences' (EW) third-quarter results.

1 month ago - Zacks Investment Research

Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Notable Edwards Lifesciences Insider Trades $4.6M In Company Stock

Michael Mussallem, Chairman And CEO at Edwards Lifesciences (NYSE:EW), made a large buy and sell of company shares on October 1, according to a new SEC filing. What Happened: A Form 4 filing from the U....

2 months ago - Benzinga

4 Stock Picks for a 'Buy and Hold' Approach

The GuruFocus business predictability rating ranks companies on a five-star scale, defining the more predictable companies as businesses whose revenue per share and Ebitda per share have been growing st...

Other symbols:CCIMCOSHW
2 months ago - GuruFocus

5 Good Companies With High Profitability

According to the “Good Companies Screen,” one of several Premium screens under the All-in-One Screener, five stocks with high financial strength and profitability are Edwards Lifesciences Corp. ( EW , F...

Other symbols:GGGLULUMASIUSNA
2 months ago - GuruFocus

4 High Ebitda Margin Stock Picks

If you want to have a higher chance to discover companies that are in good shape from a financial standpoint, you may want to consider the following four stocks, as their trailing 12-month (TTM) Ebitda ...

Other symbols:BUDCRCTMBT
3 months ago - GuruFocus

Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?

Investors are optimistic about Edwards Lifesciences (EW) on strong sales growth across all four product groups in the second quarter and raised 2021 guidance.

3 months ago - Zacks Investment Research

Final Trades: Estee Lauder, Chipotle, Abbvie & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols:ABBVCMGEL
3 months ago - CNBC Television

Edwards Lifesciences (EW) Beats on Q2 Earnings, Margins Up

Strong sales growth across all four products along with steady improvement in surgical procedure volumes during the second quarter drove Edwards Lifesciences' (EW) revenues.

4 months ago - Zacks Investment Research

Edwards Lifesciences Beats Q2 Earnings On Demand Recovery, Boosts FY2021 Guidance; Analysts Raise Price Target

Edwards Lifesciences (NYSE: EW), a cardio device company, reported Q2 earnings of $489.5 million, or $0.64, ahead of the consensus of $0.55. "Vaccine adoption in key regions has contributed to an increa...

4 months ago - Benzinga

Edwards Lifesciences (EW) Q2 Earnings and Revenues Surpass Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 16.36% and 7.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Edwards Lifesciences Reports Second Quarter Results

IRVINE, Calif., July 29, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2021.

4 months ago - PRNewsWire

Should You Buy Edwards Lifesciences (EW) Ahead of Earnings?

Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research